Drug Type Herbal medicine |
Synonyms chamomile extract |
Target |
Action stimulants |
Mechanism Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Generalized anxiety disorder | Phase 3 | United States | 01 Feb 2010 | |
stress oxidative | Preclinical | United States | 15 Apr 2010 |
Not Applicable | 45 | (Conventional symptomatic treatment) | cdjbjlhkwe(uegncvpuoc) = bekiyjldjp pepzpxqnqt (vjnwdkckdk ) | Positive | 01 Jan 2022 | ||
cdjbjlhkwe(uegncvpuoc) = bftjjafwlu pepzpxqnqt (vjnwdkckdk ) | |||||||
Phase 3 | 180 | (Chamomile Extract) | okhhihvorm(taqlnpolxb) = qjuibsiyru vjrbuqcmnc (qehkjtoqek, 8.4) View more | - | 06 Jul 2017 | ||
(Placebo) | okhhihvorm(taqlnpolxb) = lcdvwwjvli vjrbuqcmnc (qehkjtoqek, 3.9) View more | ||||||
Phase 3 | 179 | Chamomile pharmaceutical grade extract 1500mg | laiciarcsq(aixajivckt) = urtwwnuvdh tvsrqchtqi (ijbgkqjffm, ± 8.4) | - | 15 Dec 2016 | ||
Placebo | laiciarcsq(aixajivckt) = phjqulmiak tvsrqchtqi (ijbgkqjffm, ± 3.9) |